Emerging therapies forClostridium difficileinfections

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dose–Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium difficile-Associated Diarrhea Prophylaxis in Adult Patients

(2010) Xing Wang Gao et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Fidaxomicin: A Macrocyclic Antibiotic for the Management of Clostridium difficile Infection

(2010) Karyn M Sullivan et al.   ANNALS OF PHARMACOTHERAPY

Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

(2010) Stuart H. Cohen et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Purification, characterisation and identification of acidocin LCHV, an antimicrobial peptide produced by Lactobacillus acidophilus n.v. Er 317/402 strain Narine

(2010) Hermine Mkrtchyan et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Intravenous immunoglobulin for the treatment of severeClostridium difficilecolitis: An observational study and review of the literature

(2010) Marwan S. Abougergi et al.   Journal of Hospital Medicine

The dawning of a ‘Golden era’ in lantibiotic bioengineering

(2010) Des Field et al.   MOLECULAR MICROBIOLOGY

Treatment with Monoclonal Antibodies againstClostridium difficileToxins

(2010) Israel Lowy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile

(2010) M. C. Rea et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST)

(2010) Elisabeth Nagy et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Systematic review and meta-analysis ofSaccharomyces boulardiiin adult patients

(2010) Lynne V McFarland   WORLD JOURNAL OF GASTROENTEROLOGY

Fecal bacteriotherapy for recurrent Clostridium difficile infection

(2009) Johan S. Bakken   ANAEROBE

Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections

(2009) Lynne V. McFarland   ANAEROBE

Intravenous Tigecycline as Adjunctive or Alternative Therapy for Severe RefractoryClostridium difficileInfection

(2009) Bjorn L. Herpers et al.   CLINICAL INFECTIOUS DISEASES

Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria

(2009) D. M. Citron et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model

(2009) U. A. Ochsner et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors

(2009) F. Sundram et al.   JOURNAL OF HOSPITAL INFECTION

The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea

(2009) Gareth C Parkes et al.   LANCET INFECTIOUS DISEASES

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)

(2009) Brett A. Leav et al.   VACCINE

Clostridium diffcile associated infection, diarrhea andcolitis

(2009) Perry Hookman et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral Doses

(2008) Y. K. Shue et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection

(2008) T. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Renewed interest in a difficult disease: Clostridium difficile infections – epidemiology and current treatment strategies

(2008) Lynne V McFarland   CURRENT OPINION IN GASTROENTEROLOGY

OPT-80, a macrocyclic antimicrobial agent for the treatment ofClostridium difficileinfections: a review

(2008) Michael Gerber et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Antibiotic-associated diarrhea: epidemiology, trends and treatment

(2008) Lynne V McFarland   Future Microbiology

Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer

(2008) Karl Weiss   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Orally administered  -lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile

(2008) U. Stiefel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Metronidazole Resistance in Clostridium difficile Is Heterogeneous

(2008) T. Pelaez et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Meta-analysis to assess risk factors for recurrent Clostridium difficile infection

(2008) K.W. Garey et al.   JOURNAL OF HOSPITAL INFECTION